FDA Opening Up Position on CBD

Pipette with Cannabis oil against Cannabis plant

FDA Accepting Research via Forum

The FDA is opening a comment forum for CBD in correlation to their May 2019 forum. This decision is made to help the FDA gather more information on CBD and its users. In addition to gaining a better understanding of the products on the market and their uses.

 

The FDA has stated that there are no other approved CBD products outside of Epidiolex. Stating that they aren’t against the study of its usage as well as taking a stance on the potential effects. To further understand the effects of CBD, they have approved a grant to The National Center for Toxicological Research. In addition to The University of Mississippi for research into usage during pregnancy and cosmetic usage.

 

Currently they are reaching out to the industry to seek “reliable and high quality data”. Such as differences between “Full Spectrum” and “Broad Spectrum”, how they are derived, and how these compare to CBD isolate products via all modes of usage.

 

What do they know?

Through various grants the FDA hopes to combine their information with that turned in of the industry. However, any data they already have is in correlation with the drug Epidiolex. Which showed:

  • potential liver damage
  • drowsiness
  •  and male reproductive toxicity

 

Understand that there are risks associated with untested CBD products on the market such as:

  • heavy metals,
  • THC over the .3% allowed limit
  • or other contaminants

Other risks include mislabeled products and false health claims. The FDA is currently evaluating issuance of a risk-based enforcement policy to correct such illegal marketing.

 

The FDA’s final statement is they are seeking this research and data from those in the CBD space as well as evaluating marketing issuance to keep in line with their mission to protect the public, foster innovation, and promote consumer confidence.

 

North Guide Solutions is now assisting our clients in data compilation and forum posting. Also we are offering marketing reviews for our clients who sell in the CBD space as to help them avoid fines and FDA crack-downs on illegal marketing. Help further improve the FDA’s position on CBD. Call us today!

 

Full statements by FDA as well as information about Epidiolex see below:

https://www.fda.gov/news-events/press-announcements/fda-advances-work-related-cannabidiol-products-focus-protecting-public-health-providing-market?fbclid=IwAR3zFbI1tTtMWgnZMsd2asdzckdp-iDedorhE5oyGI1MO3mbm6ZMD8umpcY

https://www.fda.gov/consumers/consumer-updates/what-you-need-know-and-what-were-working-find-out-about-products-containing-cannabis-or-cannabis

https://www.fda.gov/news-events/public-health-focus/fda-and-cannabis-research-and-drug-approval-process

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/botanical-drug-development-guidance-industry

https://www.drugs.com/epidiolex.html